| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $22.5M | +6.2% | -18.7% |
| SG&A Expense | $10.1M | +6.5% | +4.8% |
| Operating Income | -$34.5M | +9.4% | +7.2% |
| Net Income | -$30.6M | +9.6% | +1.9% |
| EPS (Basic) | -$0.11 | +8.3% | +0.0% |
| EPS (Diluted) | -$0.11 | +8.3% | +0.0% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $70.2M | +6.2% | +2.0% |
| Short-term Investments | $218.2M | -7.0% | -12.7% |
| Current Assets | $299.9M | -3.5% | -9.2% |
| Total Assets | $420.4M | -5.6% | -20.5% |
| Current Liabilities | $28.7M | +2.0% | -4.4% |
| Total Liabilities |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$73.7M | — | — |
| Capital Expenditures | $119K | — | — |
| Investing Cash Flow | $75.7M | — | — |
| Financing Cash Flow | $521K | — | — |
| Free Cash Flow | -$73.9M | — | — |
| $72.5M |
| -0.8% |
| -8.0% |
| Stockholders' Equity | $347.9M | -6.5% | -22.7% |